Figure 5.

An anti–IL-5 mAb prevented the reduction in plaque size and the induction of ox-LDL antibodies in serum by IL-33. ApoE^−/− mice were treated with IL-33 (filled bars) or IL-33/αIL-5 (striped bars). (A) Plaque size (intimal area, millimeter²) in the aortic sinus (n = 5). (B) Representative photomicrographs of hematoxylin and eosin–stained aortic sections. (C) Quantification of plaque content: F4/80⁺ macrophages (percentage of total plaque area, n = 5), T cells (number of CD3⁺ T cells/ millimeter², n = 5), SMCs (percentage of total plaque area, n = 5), collagen (percentage of total plaque area, n = 5). (D) Representative photomicrographs of F4/80⁺ macrophages (brown), CD3⁺ T cells (brown), α-smooth muscle actin (brown), and collagen (blue) staining in plaques of ApoE^−/− mice treated with IL-33 or IL-33/αIL-5. (E) Ox-LDL–specific IgM antibodies in serum (n = 5). (F) IL-5 and -12 (picogram/milliliter) in serum determined by ELISA (n = 5). *, P < 0.05; **, P < 0.01, Student's unpaired t test. Bars: (B) 400 μm; (D; F4/80⁺ macrophages) 25 μm; (D; CD3⁺ T cells) 25 μm; (D; α-smooth muscle actin) 100 μm; (D; collagen) 100 μm.